Guanfacine to Treat Borderline Personality Disorder
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 4/2/2016 |
| Start Date: | July 2006 |
| Contact: | Emily Hart |
| Email: | mpgroup@mssm.edu |
| Phone: | (212) 241-4459 |
Guanfacine in the Treatment of Borderline Personality Disorder
This study is designed to investigate whether guanfacine (Tenex) is an effective treatment
for borderline personality disorder (BPD), an illness often characterized by unstable mood
and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain,
a region associated with attention and the control of behavior. We believe that guanfacine
may improve symptoms of BPD by improving attention and aiding regulation of behavior.
for borderline personality disorder (BPD), an illness often characterized by unstable mood
and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain,
a region associated with attention and the control of behavior. We believe that guanfacine
may improve symptoms of BPD by improving attention and aiding regulation of behavior.
This is an 8-week treatment study designed to test whether guanfacine is an effective
treatment for borderline personality disorder (BPD). Prior to taking the study medication,
subjects will have medical and psychiatric evaluations, complete self-report questionnaires,
do a functional MRI scan, and complete a set of cognitive tests. While taking the study
medication, participants will meet weekly with a study doctor and be administered interviews
and questionnaires. At the end of the 8-week trial, participants will be asked to repeat the
MRI scan and cognitive tests.
treatment for borderline personality disorder (BPD). Prior to taking the study medication,
subjects will have medical and psychiatric evaluations, complete self-report questionnaires,
do a functional MRI scan, and complete a set of cognitive tests. While taking the study
medication, participants will meet weekly with a study doctor and be administered interviews
and questionnaires. At the end of the 8-week trial, participants will be asked to repeat the
MRI scan and cognitive tests.
Inclusion Criteria: This study includes men and women between the ages of 18 and 55 who
meet criteria for borderline personality disorder with impulsive aggression.
Exclusion Criteria: Subjects must not currently be taking any psychiatric medications.
Subjects must not meet criteria for current substance dependence, current major
depression, bipolar disorder, or schizophrenia-spectrum disorders.
We found this trial at
1
site
Click here to add this to my saved trials
